The trial may take longer if each potential patient is tested for ccr5 density. But the upside is that CYDY will most likely include patients who through the density test have a higher probability of a positive response to Leronlimab. This will hopefully ensure positive data, or at least that’s how I interpret what they’re doing (in addition to finding the optimal dose).